Literature DB >> 19208857

Whole body overexpression of PGC-1alpha has opposite effects on hepatic and muscle insulin sensitivity.

Huiyun Liang1, Bogdan Balas, Puntip Tantiwong, John Dube, Bret H Goodpaster, Robert M O'Doherty, Ralph A DeFronzo, Arlan Richardson, Nicolas Musi, Walter F Ward.   

Abstract

Type 2 diabetes is characterized by fasting hyperglycemia, secondary to hepatic insulin resistance and increased glucose production. Peroxisome proliferator-activated receptor-gamma coactivator-1alpha (PGC-1alpha) is a transcriptional coactivator that is thought to control adaptive responses to physiological stimuli. In liver, PGC-1alpha expression is induced by fasting, and this effect promotes gluconeogenesis. To examine whether PGC-1alpha is involved in the pathogenesis of hepatic insulin resistance, we generated transgenic (TG) mice with whole body overexpression of human PGC-1alpha and evaluated glucose homeostasis with a euglycemic-hyperinsulinemic clamp. PGC-1alpha was moderately (approximately 2-fold) overexpressed in liver, skeletal muscle, brain, and heart of TG mice. In liver, PGC-1alpha overexpression resulted in increased expression of hepatocyte nuclear factor-4alpha and the gluconeogenic enzymes phosphoenolpyruvate carboxykinase and glucose-6-phosphatase. PGC-1alpha overexpression caused hepatic insulin resistance, manifested by higher glucose production and diminished insulin suppression of gluconeogenesis. Paradoxically, PGC-1alpha overexpression improved muscle insulin sensitivity, as evidenced by elevated insulin-stimulated Akt phosphorylation and peripheral glucose disposal. Content of myoglobin and troponin I slow protein was increased in muscle of TG mice, indicating fiber-type switching. PGC-1alpha overexpression also led to lower reactive oxygen species production by mitochondria and reduced IKK/IkappaB signaling in muscle. Feeding a high-fat diet to TG mice eliminated the increased muscle insulin sensitivity. The dichotomous effect of PGC-1alpha overexpression in liver and muscle suggests that PGC-1alpha is a fuel gauge that couples energy demands (muscle) with the corresponding fuel supply (liver). Thus, under conditions of physiological stress (i.e., prolonged fast and exercise training), increased hepatic glucose production may help sustain glucose utilization in peripheral tissues.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19208857      PMCID: PMC2670619          DOI: 10.1152/ajpendo.90292.2008

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  48 in total

Review 1.  Metabolic and molecular basis of insulin resistance.

Authors:  Mandeep Bajaj; Ralph A Defronzo
Journal:  J Nucl Cardiol       Date:  2003 May-Jun       Impact factor: 5.952

2.  PGC-1alpha mRNA expression is influenced by metabolic perturbation in exercising human skeletal muscle.

Authors:  Jessica Norrbom; Carl Johan Sundberg; Helene Ameln; William E Kraus; Eva Jansson; Thomas Gustafsson
Journal:  J Appl Physiol (1985)       Date:  2003-09-12

3.  p38gamma MAPK regulation of glucose transporter expression and glucose uptake in L6 myotubes and mouse skeletal muscle.

Authors:  Richard C Ho; Oscar Alcazar; Nobuharu Fujii; Michael F Hirshman; Laurie J Goodyear
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2003-10-30       Impact factor: 3.619

4.  PGC-1 promotes insulin resistance in liver through PPAR-alpha-dependent induction of TRB-3.

Authors:  Seung-Hoi Koo; Hiroaki Satoh; Stephan Herzig; Chih-Hao Lee; Susan Hedrick; Rohit Kulkarni; Ronald M Evans; Jerrold Olefsky; Marc Montminy
Journal:  Nat Med       Date:  2004-04-25       Impact factor: 53.440

5.  NF-kappaB activation and iNOS upregulation in skeletal muscle of patients with COPD and low body weight.

Authors:  A Agustí; M Morlá; J Sauleda; C Saus; X Busquets
Journal:  Thorax       Date:  2004-06       Impact factor: 9.139

6.  Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction.

Authors:  Pere Puigserver; James Rhee; Jerry Donovan; Christopher J Walkey; J Cliff Yoon; Francesco Oriente; Yukari Kitamura; Jennifer Altomonte; Hengjiang Dong; Domenico Accili; Bruce M Spiegelman
Journal:  Nature       Date:  2003-05-18       Impact factor: 49.962

7.  Exercise induces transient transcriptional activation of the PGC-1alpha gene in human skeletal muscle.

Authors:  Henriette Pilegaard; Bengt Saltin; P Darrell Neufer
Journal:  J Physiol       Date:  2003-02-01       Impact factor: 5.182

Review 8.  Pathogenesis of type 2 diabetes mellitus.

Authors:  Ralph A DeFronzo
Journal:  Med Clin North Am       Date:  2004-07       Impact factor: 5.456

9.  Regulation of hepatic fasting response by PPARgamma coactivator-1alpha (PGC-1): requirement for hepatocyte nuclear factor 4alpha in gluconeogenesis.

Authors:  James Rhee; Yusuke Inoue; J Cliff Yoon; Pere Puigserver; Melina Fan; Frank J Gonzalez; Bruce M Spiegelman
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-21       Impact factor: 11.205

10.  PGC-1beta in the regulation of hepatic glucose and energy metabolism.

Authors:  Jiandie Lin; Paul T Tarr; Ruojing Yang; James Rhee; Pere Puigserver; Christopher B Newgard; Bruce M Spiegelman
Journal:  J Biol Chem       Date:  2003-06-13       Impact factor: 5.157

View more
  36 in total

1.  Impairment of PGC-1alpha expression, neuropathology and hepatic steatosis in a transgenic mouse model of Huntington's disease following chronic energy deprivation.

Authors:  Rajnish K Chaturvedi; Noel Y Calingasan; Lichuan Yang; Thomas Hennessey; Ashu Johri; M Flint Beal
Journal:  Hum Mol Genet       Date:  2010-06-07       Impact factor: 6.150

2.  PGC-1α overexpression exacerbates β-amyloid and tau deposition in a transgenic mouse model of Alzheimer's disease.

Authors:  Magali Dumont; Cliona Stack; Ceyhan Elipenahli; Shari Jainuddin; Nathalie Launay; Meri Gerges; Natalia Starkova; Anatoly A Starkov; Noel Y Calingasan; Davide Tampellini; Aurora Pujol; M Flint Beal
Journal:  FASEB J       Date:  2014-01-07       Impact factor: 5.191

Review 3.  Dissociating fatty liver and diabetes.

Authors:  Zheng Sun; Mitchell A Lazar
Journal:  Trends Endocrinol Metab       Date:  2012-10-05       Impact factor: 12.015

4.  Maintaining PGC-1α expression following pressure overload-induced cardiac hypertrophy preserves angiogenesis but not contractile or mitochondrial function.

Authors:  Renata O Pereira; Adam R Wende; Ashley Crum; Douglas Hunter; Curtis D Olsen; Tenley Rawlings; Christian Riehle; Walter F Ward; E Dale Abel
Journal:  FASEB J       Date:  2014-04-28       Impact factor: 5.191

5.  The Cancer Drug Dasatinib Increases PGC-1α in Adipose Tissue but Has Adverse Effects on Glucose Tolerance in Obese Mice.

Authors:  Lykke Sylow; Jonathan Z Long; Isha A Lokurkar; Xing Zeng; Erik A Richter; Bruce M Spiegelman
Journal:  Endocrinology       Date:  2016-09-02       Impact factor: 4.736

Review 6.  Genetic models of PGC-1 and glucose metabolism and homeostasis.

Authors:  Glenn C Rowe; Zoltan Arany
Journal:  Rev Endocr Metab Disord       Date:  2014-03       Impact factor: 6.514

Review 7.  PGC-1α activation: a therapeutic target for type 2 diabetes?

Authors:  Daixiu Yuan; Dingfu Xiao; Qian Gao; Liming Zeng
Journal:  Eat Weight Disord       Date:  2018-11-29       Impact factor: 4.652

Review 8.  PGC-1alpha regulation by exercise training and its influences on muscle function and insulin sensitivity.

Authors:  Vitor A Lira; Carley R Benton; Zhen Yan; Arend Bonen
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-04-06       Impact factor: 4.310

Review 9.  Functional crosstalk of PGC-1 coactivators and inflammation in skeletal muscle pathophysiology.

Authors:  Petra S Eisele; Christoph Handschin
Journal:  Semin Immunopathol       Date:  2013-11-21       Impact factor: 9.623

10.  Differential regulation of PGC-1alpha expression in rat liver and skeletal muscle in response to voluntary running.

Authors:  Renata Matiello; Rosa T Fukui; Maria Er Silva; Dalva M Rocha; Bernardo L Wajchenberg; Salman Azhar; Rosa F Santos
Journal:  Nutr Metab (Lond)       Date:  2010-04-30       Impact factor: 4.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.